For research use only. Not for therapeutic Use.
Cendakimab（Cat No.:I042143）is an investigational monoclonal antibody that targets and inhibits IL-13 (interleukin-13), a cytokine involved in immune system regulation and inflammation. IL-13 plays a key role in the pathogenesis of various inflammatory conditions, including asthma, atopic dermatitis, and eosinophilic esophagitis. By blocking IL-13, cendakimab aims to reduce inflammation and modulate the immune response, potentially improving disease control and symptoms in patients. It is being studied in clinical trials for its potential to treat a range of allergic and inflammatory diseases, with a focus on enhancing patient outcomes and quality of life.
| Catalog Number | I042143 |
| CAS Number | 2151032-62-9 |
| Purity | ≥95% |
